Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

VRXA

$1.65+3.12%

Veraxa Biotech AG - Post de-SPAC

Market Cap
—
Sector
—
Industry
—
Beta
0.01
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
24.9x
buying
Congress
—
recent trades
Short Volume
55%
W/W +11.7pp

Market & Alt Data

News
8
recent articles
Activist
13D
Deck
Velocity Score
24.85x
Current Rate (90d)
611.11/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
2
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-272026-08-31Antz Christoph RudigerDirector & Chief Executive OfficerPurchase5,000$1.53$8K5,000View
2026-08-272026-08-31Baumann Oliver RolfDirectorPurchase50.0K$1.50$75K5.77MView

Recent News

VERAXA Biotech Designates Raju Willener as CFO
Yahoo Finance · 2026-09-09
VERAXA Biotech (VRXA) Appoints Raju Willener as Chief Financial Officer
Yahoo Finance · 2026-09-08
VERAXA Biotech (VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
Yahoo Finance · 2026-08-06
VERAXA Biotech (VRXA) Shareholders Approve Corporate Governance, Financing Measures
Yahoo Finance · 2026-07-28

Informational purposes only, not investment advice.

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
Yahoo Finance · 2026-07-27
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
Yahoo Finance · 2026-07-23
VERAXA Biotech (VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
Yahoo Finance · 2026-07-20
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
Yahoo Finance · 2026-07-20

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →